During the past fifteen years it has become possible to inhibit or at least to diminish intravascular clotting in patients by the use of anticoagulant drugs. This has opened up a large field in the treatment and prevention of thrombo-embolic disease.
Heparin?a polysaccharide containing glucuronic and sulphuric acid esters?was the first anticoagulant to be used clinically on a large scale by Murray in Canada and by Crafoord in Sweden in the mid J930s. In 1939-40 Link and his associates synthesised dicoumarol, 3, 3 methylene bis (4 hydroxy coumarin) (Stahmann et al., 1941) , and in 1948 Reinis and Kubik reported on the clinical use of another coumarin drug, an ethyl ester of 4 (hydroxy coumarinyl) acetic acid, known as pelentan or tromexan. Reports have also been forthcoming of the clinical use of several other substances, chief of which are paritol, a synthetic heparinoid substance, and phenylindanedione, the former being originally reported on by Sorensen and Wright (1950) and the latter by Soulier and Gueger (1947) , while at a meeting of the Royal Society of Medicine, Walton (1951) reported on the anticoagulant activity of preparations of dextran sulphate. The anticoagulant effect ?f salicylates has also invited some attention, but massive doses are usually required to attain a useful prolongation of clotting. To date, these drugs do not appear to have been used to any great extent for their anticoagulant action, but this action should be borne in mind when Patients are on dicoumarol or tromexan therapy because salicylates are in common use for minor aches and pains and habitual users seldom think of volunteering the fact. The unsuspected use of salicylates ftiay on occasion account for an apparent undue susceptibility to dicoumarol or tromexan.
During the last ten years anticoagulant therapy has been employed *n Sir James Learmonth's unit in 382 cases. The drugs used were heparin, dicoumarol or tromexan, and I propose therefore to limit discussion in this paper to our experience with these drugs with regard to their action, control of dosage, difficulties and dangers which have been encountered, and to deal briefly with the duration and results of treatment.
Heparin Action and Administration.?Heparin, which acts directly on the dotting mechanism as an antithrombin, antithromboplastin and Probably antiprothrombin, takes effect as soon as it comes in contact A Honyman Gillespie Lecture delivered in Edinburgh on 15th May 1952 VOL. LXT. NO. 8 273 S with blood. The anticoagulant potency of the commercial preparations is expressed in international units, and solutions of iooo I.U./c.c., 5000 I.U./c.c. and 25,000 I.U./c.c. are available. It can be given by intravenous, intramuscular or subcutaneous injection in doses for an adult of from 7500 units up to 12,500 units. Within a few minutes after intravenous injection of heparin the clotting time of the blood is prolonged. However, the drug is rapidly excreted by the kidneys, some of it being fixed in the tissues, and three to four hours later the clotting time has usually returned to normal. We consider that intravenous injection is the safest method of administering the drug. Indwelling needles and polythene tubing have been advocated as a means of avoiding the need of repeated venepunctures. When this intermittent intravenous method is used, it is advisable to give the drug 4-hourly for the first day or two, then as clinical symptoms improve to drop it to 8-hourly, then to twice a day and finally to once a day for several days. If heparin is stopped too abruptly, patients sometimes appear to pass into a phase with an increased tendency to clot. In our early cases we estimated the whole blood clotting time before and one hour after each dose, but ceased to do this several years ago.
Continuous intravenous drip was used only in early cases of our series.
With this method an initial boosting dose of 5000 units must be given into the drip tubing, and thereafter 5000-10,000 units of heparin put in each flask. The rate of the drip has to be regulated so that sufficient heparin is given to maintain the clotting time at the desired level which is looked upon as being somewhere in the region of 15 to 20 minutes (Lee and White). This necessitates estimation of clotting times at two to three hourly intervals, otherwise there is danger of either over-or under-dosage. When administered by the intramuscular route, the absorption of heparin is slower. In our experience, following a single dose the maximum clotting time attained is seldom as high as 20 minutes (Lee and White), but it may remain elevated above the control level (5-8 minutes) for periods of 5 or 6 hours. However, when intramuscular injections are repeated at frequent intervals, a depot is gradually built up, and we have found that in adults in the post-operative state it may be dangerous to continue 4-hourly intramuscular injections of heparin for longer than 24 hours without clotting time estimation.
Painful haematomata are frequently complained of by patients who have been given repeated intramuscular injections of heparin for prolonged periods. The extent of bruising which may appear in such cases is illustrated in Fig. 1 . Loewe and Rosenblatt (1944) advocated the administration of heparin in a pitkin menstruum to slow up the rate of absorption and to give a prolonged action, while some workers advocate the administration of 15,000 or even 25,000 units of the concentrated preparation at infrequent intervals, possibly only once m 24 hours. In my opinion, a depot of this size could be dangerous in the post-operative stage.
The subcutaneous route has seldom been used because of erratic absorption and the large and visible bruising which appears at the site of injection. Tuckman and Moolten (1950) advocated the use of a subcutaneous depot of hyaluronidase as a means of achieving rapid absorption of heparin injected into this area. We have used this method in a few cases, but the results have been less predictable than with the intravenous and intramuscular routes, although prolongation of the clotting time up to 15 minutes over a period of 2 hours has been achieved.
The method is, moreover, not always painless : several patients have complained of discomfort at the site of the injection. However, only moderate bruising has been noted, even after four injections in 24 hours.
In 1951 Litwins and others reported successful prolongation of the clotting time in a number of patients following the administration of heparin by the sublingual route. They stated that in all cases a rise occurred within 30 minutes which reached a maximum in 1 to 2 hours and lasted for from 3 to 7 hours. It seemed that if this were so it would be a most useful method of administration, and we attempted to repeat their study. Sublingual tablets which contained 10,000 units of heparin "Were obtained and used in 5 cases. In one case the clotting time by the Lee and White method rose from 8 minutes to 12 minutes one hour after administration ; it was 11 minutes 2 hours after and had returned to 8 minutes 3 hours after administration. In the 4 other cases given 10,000 or 20,000 units of heparin the clotting time was unaltered.
Kennedy and Brown (1952) have recently reported a similar failure to prolong the blood coagulation time by sublingual administration of heparin.
Side Effects.?Heparin in itself is a non-toxic substance, but idiosyncrasy to it does occur, and in 5 of our patients immediately after an intravenous injection there was a complaint of dyspnoea, discomfort in the chest, a feeling of heat in the head accompanied by flushing and tachycardia. The symptoms were transient in all cases, but were frightening for both the patient and onlooker. In one patient similar symptoms were produced by a subsequent injection and treatment had to be discontinued. In the others the intramuscular route "Was substituted for the intravenous route without further trouble.
It has been suggested that heparin may have a vasodilator effect, and in a number of our cases ischaemic pain, unrelieved by morphine, disappeared within a few minutes of the intravenous injection of heparin (Burt, 1947 ). An attempt was therefore made to measure the vasodilator effect, if any, but plethysmographic recordings of hand blood flow in two subjects before and for one hour after the intravenous injection ?f heparin failed to show any increase in blood flow. However, on several occasions rigors and pyrexia have appeared half an hour to an hour after intravenous injection of heparin. This reaction was similar to that following intravenous injection of T.A.B. or other foreign Protein. It seems possible, therefore, that a moderate vasodilator effect might be due to a minor reaction of this type, probably caused by protein contaminant in the preparation of heparin.
It has been suggested that one of the useful side actions of heparin may be to enhance the fibrinolytic activity of the blood and thus encourage lysis of pre-formed clot. In 10 cases fibrinolytic activity of the blood was investigated during anticoagulant therapy with heparin. In no case was there any evidence to indicate an increase during the period of therapy. However, Macfarlane and Biggs (1946) have shown that transient fibrinolytic activity occurs in man following psychological and operative trauma, exercise, and the administration of adrenaline. Therefore it would seem that any clot formed during operation or in a period of psychological trauma might contain fibrinolysin. We have found in vitro that rapid complete lysis of a fibrin clot is dependent upon intimate mixing of the fibrinolysin with the plasma before clotting occurs. If the fibrinolysin is added after clotting has occurred, only the first 2 or 3 mm. of the clot in direct contact with the fibrinolysin becomes lysed in 24 hours. From this it would seem possible that clot formed in the immediate post-operative period may contain fibrinolysin and thus be less durable than clot formed after the alarm reaction has subsided. Rapid lysis of clot may account for the infrequency of thrombotic complications in the immediate post-operative period. It also seems unlikely that subsequent fibrinolytic activity, however induced, will materially affect pre-formed massive clot in blood vessels.
However, if the clot is spread thinly over a large raw area, the whole of this clot might well be removed by subsequent fibrinolytic activity. This may explain the excessive haemorrhage which is feared by most workers when patients are put on anticoagulant therapy following operations such as prostatectomy.
Although we have not obtained any direct experimental evidence of lysis of pre-formed clot, clinical evidence suggests that provided a thrombus is of recent origin, recanalisation is favoured by anticoagulant therapy whether by heparin or by tromexan. It may be that this therapy allows a greater degree of natural fibrinolysis to occur by inhibiting further spread of non-lysin containing thrombus. Fig. 2 illustrates the spread of thrombus and recanalisation in the forearm veins in a case of recurrent venous thrombosis. Recanalisation occurred in all veins except for 2 cm. where the primary thrombosis had occurred. It is possible that organisation had already started in this area before anticoagulant therapy was instituted.
Antagonists.?The action of circulating heparin can be rapidly terminated by the intravenous administration of a 1 per cent, solution of protamine sulphate, or by toluidine blue. We have used only the former clinically, and have found it useful in doses of from 1 to 5 c.c. It will cause a reduction in the clotting time within a few minutes of administration in vivo. In vitro, however, the effective concentration needed may be about 10-16 times the amount required in vivo, and has to be determined in each case by the use of serial dilutions of protamine. ?Photograph to illustrate petechial haemorrhage confined to the affected limb in patient with deep venous thrombosis who was on anticoagulant therapy. This patient had had a drip into the saphenous vein of this leg which had been followed early by thrombosis of the saphenous vein. In addition to the petechial haemorrhages a hematoma lormed at the site of the venepuncture. IG-6.?Photograph to illustrate petechial haemorrhage confined to the affected limb in a patient with deep venous thrombosis who was on anticoagulant therapy. This patient had had a drip into the saphenous vein of this leg which had been followed early by thrombosis of the saphenous vein. In addition to the petechial haemorrhages a ha'matoma formed at the site of the venepuncture.
Concentrations above or below this critical level have an anticoagulant effect and cause further prolongation of clotting time. This effect has not been reported to occur in vivo.
The following case shows the danger of prolonged 4-hourly intramuscular administration of heparin without clotting time estimation as a control, and serves to illustrate the need of prolonged transfusion and repeated protamine injection when a heparin depot is present.
Fifteen days after total gastrectomy, a male patient aged 55 developed an ileo-femoral thrombosis. In view of the extensive operation, heparin was regarded as the drug of choice, and the patient was put on 10,000 units of heparin intravenously at 4-hourly intervals f?r 24 hours and thereafter at 6-8-hourly intervals by intramuscular ejection. His symptoms failed to improve on this dosage, and on the twentieth post-operative day it was increased to 10,000 units 4-hourly lntramuscularly. 
Coumarins?Anti-prothrombin Agents
Dicoiimarol and Tromexan.?These differ from heparin in that their action is not on the clotting mechanism itself but on the inhibition of formation of one of the clotting factors. They are both administered by mouth. Dicoumarol is prepared in 50 mg. tablets, and pelentan or tromexan in 300 mg. tablets.
Reinis and Kubik (1948) reported that weight for weight the anticoagulant activity of dicoumarol is approximately four times that of tromexan. In our patients, the initial dose of dicoumarol used was 200-300 mg. on the first day, and of pelentan or tromexan 0-9-1 -2 g. The dosage of both drugs has to be controlled by estimation of the so-called " prothrombin time " which is merely an accelerated plasma clotting time where excess thromboplastin and calcium are added to citrated or oxalated blood. A prothrombin time prolonged beyond control levels indicates a low level of prothrombin activity and vice versa. There is no absolute normal value for prothrombin time because it depends largely on the potency of the thromboplastin in use. Times for normal plasma have been recorded which vary between 10 seconds and 25 seconds, and it is necessary to know the range of normal in the thromboplastin which is being used. The more potent the thromboplastin the smaller is the rise in clotting time with diminished levels of prothrombin. Many workers state that an effective therapeutic dose of dicoumarol or tromexan is attained only when the prothrombin time of the patient under treatment is 2-2I times that of normal. This may be true when a moderately weak thromboplastin is being used, that is when the normal time is 16-20 seconds, but if the thromboplastin in use gives a normal range of between 10 and 13 seconds, then times of 15-25 seconds may be comparable to those of 30-40 seconds given by the weaker thromboplastin. In some laboratories it has been the habit to report on the blood sent for testing by giving a value of prothrombin activity expressed as a percentage of normal. This is worked out by the use of dilution curves (Fig. 3 ). We have mainly used Fullerton's method with viper venom for prothrombin time estimation, but during the past year have duplicated the tests, using in addition Quick's one-stage method with brain thromboplastin. In general, good correlation has been found, but as Macfarlane and others have pointed out, the use of Quick s method shows a greater rise in " clotting time "
with minor depressions of prothrombin activity than is shown by Fullerton's method, and is therefore probably the safer to use. We have found, however, that Fullerton's method gives more consistent results. There have been occasions when the clotting times of the same plasma have differed widely with the two methods. In one case a female patient, aged 3^' who had had an acute arterial block, had been on anticoagulant therapy for 8 days. On the ninth day the viper venom prothrombin time was 14-7 seconds (control 14 seconds) whereas the brain thromboplastin time was 38-3 seconds (control 12 seconds). As there had been considerable clinical improvement in the condition of her foot, it was decided to take the longer time as probably representing the true state of affairs. Her dose of tromexan was therefore not increased. During the next 24 hours the limb became swollen and the foot gangrenous.
Further prothrombin time estimations still showed the same short viper venom and long brain thromboplastin times, but whole blood clotting time was normal and amputation was performed without undue bleeding. Examination of the amputated limb disclosed widespread recent thrombosis in the calf veins in addition to the old arterial block.
The reason for the prolonged brain thromboplastin prothrombin time in this case is not known, but may have been due to ageing of the thromboplastin which sometimes occurs suddenly. In other cases When surprisingly long prothrombin times have been found, contamination of the syringe with heparin has been suspected and occasionally Proved by protamine titration.
For a time it was generally accepted that the prothrombin time of blood was unaffected by the administration of heparin, but as was shown by Long et al. (1946) , the prothrombin time may be prolonged lmrnediately after an intravenous dose of heparin. It has therefore 3.?Prothrombin time curves with varied dilutions of plasma in five normal controls using viper venom thromboplastin.
3.?Prothrombin time curves with varied dilutions of plasma in five normal controls using viper venom thromboplastin. 28o been our practice to see that in patients on combined heparin and coumarin therapy, blood is withdrawn when the heparin effect is at its minimum, that is, at least 4 hours after intravenous and 6 hours after the last intramuscular injection. When frequent doses of intramuscular heparin are used, the patient is continuously under the influence of heparin and quite a large error may be made in prothrombin time estimation and must be allowed for. In such cases the true prothrombin time should be determined after addition of appropriate quantities of protamine sulphate or toluidine blue. For example, in a patient who had been on intramuscular heparin and had been given 1*2 g. of tromexan, the prothrombin time 24 hours afterwards was 31 seconds ; this was reduced to 23 seconds by the addition of 0-05 c.c. of 1/2000 protamine sulphate to o-i c.c. plasma in the clotting system.
In our series of cases dicoumarol was used during the first 6 years of the 10 years under review, and a typical response is illustrated in Fig. 4 . The rise in prothrombin time to double the control level is slow, and the longest prothrombin times occur several days after the dose has been diminished, while the prothrombin time is still elevated well above the control level 5 days after the last dose of 100 mg. This initial lag and prolonged action make dicoumarol difficult to control during long-term therapy, but other workers have reported that good results are obtained by intermittent dosage, such as giving the drug on 3 days in the week.
In our experience tromexan has proved an easier drug to handle, and although as in the case of dicoumarol individual requirements vary widely, once they have been established we have found them to remain fairly constant except when systemic upsets occur. Fig. 5 illustrates the prothrombin activity expressed as a percentage of normal in a patient with deep venous thrombosis of the right leg, in whom initial therapy was inadequate and was stopped too early and thrombosis occurred in the left leg 5 days after. The first part of the graph also illustrates the disturbance which heparin can cause in prothrombin estimation.
The initial level of 35 per cent, was probably quite erroneous.
The second part of the graph shows the more typical smooth curve obtained with tromexan alone, and also shows the gradual return to normal levels to permit start of massage without danger of bruising.
Antagonists.?There is no quick way of inhibiting the action of dicoumarol or tromexan, and if dangerous bleeding occurs during therapy, transfusion with blood is the only way of restoring normal clotting function ; if severe over-dosage has occurred transfusion may have to be repeated daily for some days.
Vitamin K in doses of 200 mg. or more has been regarded as an antidote to dicoumarol and tromexan, but doubt has been thrown on its efficacy in recent publications by Stirling and Hunter (1951) and by Douglas and Brown (1952) , who advocate the intravenous or oral use of the analogue vitamin Kx (2 methyl-3-phytyl-i : 4 naphthoquinone). Out-Patient Therapy.?Initially we considered that it was unjustifiable to treat any subject as an out-patient in view of the danger of over-dosage and bleeding from mucous membranes or undue bruising from slight trauma. We were forced to change our views by the following case.
In September 1948 a male patient aged 48 was admitted to Dr W. A. Alexander's ward in the Royal Infirmary, Edinburgh, with a left pulmonary embolus which had occurred one week previously and was accompanied by haemoptysis. Gross swelling and oedema of the left leg were also present. Relevant previous history included an attack of pain in the right loin in April 1948. An intravenous pyelogram at that time was negative, but the patient stated that for some weeks following this he noticed redness and pain over the veins of the left forearm. In June 1948 migratory phlebitis had appeared in the left saphenous territory.
He was treated with heparin, 10,000 units 4-hourly, then 6-hourly, dropping to thrice daily and twice daily as clinical improvement was noted. Ligature of the left saphenous vein was performed on 28.9.48 under cover of daily doses of heparin, 10,000 units. On the night of 1.10.48 signs of a left pulmonary embolus appeared and full heparinisation was reinstituted. Pelentan was substituted for heparin on 26.10.48. His initial prothrombin time was 12 seconds (control 15 seconds), but after 1 -2 g. of pelentan for three days this rose to 23 seconds (control 13 seconds). Thereafter a level of between 20 and 40 seconds was maintained on doses of o-6 g. daily with occasionally 0-9 g. on a third day. Following a course of X-ray baths in November to December 1948, he became more sensitive to pelentan and until the end of January 1949 doses of 0-6 g., 0*3 g. and o g. in a 3-day cycle were sufficient to maintain the prothrombin time at the previous levels. The larger doses then had to be reintroduced.
He was allowed home in February 1949 on a maintenance dose of ?"3 ?'6 g-, o-6 g., in 3-day cycles, with occasional doses of 0-9 g. He was readmitted to hospital on several occasions in the following year with signs of over-dosage and under-dosage. For example, in July 1949 he had a severe epistaxis when dicoumarol, 100 mg. daily, had been substituted for pelentan during a temporary shortage of the latter drug. Several attempts to stop anticoagulant therapy during this year were all followed by an exacerbation of symptoms and spread of thrombosis to the right external jugular vein, right leg, both arms, and on one occasion when therapy had been stopped for one day because of slight haematuria, a right hemiplegia developed. On the following day this responded rapidly to heparinisation and to increase in pelentan. In August 1949 suspicion that he had an underlying neoplasm was confirmed by the appearance of nodules in the right posterior triangle of the neck. Biopsy of one of these indicated that they were secondary deposits of spheroidal cell carcinoma but no primary site could be suggested. Treatment with tromexan was continued at home and by this time venepuncture had become difficult because so many superficial veins had been previously thrombosed. Dosage was therefore regulated by clinical findings, and he remained fairly well on tromexan 0-3 g., o-6 g., o-6 g. with occasionally 0-9 g. until April 1950 when he had severe pain in the left loin followed by fever and haematuria. His doctor stopped the anticoagulant therapy, justly considering that the haematuria was probably due to over-dosage, but the patient developed a left hemiplegia and died five days later, having refused to return to hospital. Permission was obtained to perform a limited autopsy at home, and the cause of the haematuria was found to be thrombosis or embolism of both renal arteries. In the right renal artery the block was of recent origin while the left renal artery showed an unusual degree of recanalisation which the pathologist attributed to the action of anticoagulants. It is of interest to note that although the patient had for 20 months been on quite large doses of pelentan and tromexan, the liver did not show any gross pathology. The site of the primary neoplasm was not found, but may have been the thyroid gland which could not be examined.
Following this experience, we have used long-term anticoagulant therapy in a small group of patients with thrombo-angiitis obliterans and recurrent phlebitis in whom we thought the risk was justified by the poor prognosis if the condition progressed, and at present we are trying it in a small group of patients with arteriosclerosis obliterans.
The dangers are explained to the patients and their co-operation is obtained before start of therapy.
Complications.?The complications and side effects which occurred under heparin therapy have already been discussed. In the patients treated with the coumarin preparations, the commonest complication was haematuria, major episodes of which occurred in 10 cases ; the majority of these were in cases of operation upon the renal tract.
Haematemesis occurred in 3 patients put on anticoagulant therapy because of post-operative venous thrombosis following vagotomy (1 case) and gastrectomy (2 cases). In each case the peptic ulcerbearing area was intact after operation and it is considered that this may well have been the site of haemorrhage. In one patient on dicoumarol, a large haematoma which caused a transient sciatic nerve palsy occurred following a penicillin injection given when the prothrombin time was 30 seconds. Widespread subcutaneous or petechial haemorrhages occurred in 5 patients, 2 of whom had received prolonged heparin therapy. In a third patient it occurred at the site of an urticarial rash, in the fourth following a prolonged period of venous occlusion a difficult venepuncture, and in the fifth was confined to the grossly ?edematous and swollen limb for which the patient was receiving therapy (Fig. 6 ). In this patient capillary resistance was normal and her prothrombin time was 27 seconds (control 14-5 seconds). It may be of some interest to record that during the first three days of combined heparin-tromexan therapy in a patient who had had a skin graft for a leg ulcer, sero-sanguinous fluid, secreted in large quantities, floated the graft off the surface ; nevertheless the graft finally took well.
Choice of Anticoagulant
In the series under discussion heparin was the anticoagulant of choice in cases where a rapid action was wanted, or where it seemed that it might be desirable or necessary to terminate anticoagulant therapy rapidly. In 50 cases heparin only was used, and heparin was also given for the first two or three days in conjunction with dicoumarol (60 cases) and with tromexan (272 cases). Treatment (a) Chronic Obliterative Arterial Disease.?Of the 382 patients reported in this paper, 69 were patients with chronic obliterative arterial disease, 45 of whom had gangrene or ulceration of toes at the time of admission and 24 had signs of ischaemia of lesser degree. Of the 45 who were admitted with gangrene or ulceration, 13 improved and were discharged from hospital with their lesions healed or healing after a period of anticoagulant therapy which varied from 2 weeks to 2 months. In 29 patients amputation became necessary. Three died from progression of their disease. Of the 24 patients without gangrene, 5 progressed to amputation, 3 died from progression of the disease soon after anticoagulant therapy had been discontinued.
Of the other 16, 7 improved and 9 are still on out-patient long-term therapy with tromexan.
(&) Acute Arterial Occlusion.?A group of 28 cases of acute arterial occlusion were treated conservatively by anticoagulants and reflex heating. Pulses, temperature, motor and sensory findings were recorded at frequent intervals and if improvement occurred anticoagulant therapy was continued (Fig. 7) . Fifteen of these patients improved and were discharged from hospital. In 4 the limb did not improve and amputation became necessary. Eight died from the effects of other emboli, and one, a male aged 60, died from cerebral haemorrhage at a time when his prothrombin time was 33 seconds against a control of 15 seconds which would be generally regarded as a safe therapeutic evel. It seems probable, however, that if a patient develops a small Cerebral haemorrhage while on this therapy, the effect of the antic?a-gulant will be to convert a minor into a major and fatal haemorrhage arid this may have happened in this case.
Sixteen cases of arterial embolism were treated by embolectomy ?W?wed by anticoagulant therapy within 6 hours of operation. Some these cases were initially treated conservatively, but as they had Fig. 8 .?To illustrate a case of arterial embolism in which the condition of the limb showed initial improvement but later regression under conservative treatment with anticoagulants. Fig. 8 .?To illustrate a case of arterial embolism in which the condition of the limb showed initial improvement but later regression under conservative treatment with anticoagulants.
failed to improve in the first few hours, operation was decided upon (Fig. 8 ). In this group 5 recovered. Of these, 4 had had aortic emboli and one had had a mesenteric embolus. Four who had had emboli in the femoral or popliteal vessels lost the affected limbs, and 7 died from other embolic episodes. Anticoagulants were given within 6 hours of operation to an additional 15 patients making a total of 31. Troublesome haemorrhage necessitating cessation of anticoagulant therapy occurred in 5 of these patients and probably contributed to the fatal outcome in a sixth.
(c) Deep Venous Thrombosis.?-Two hundred cases of deep venous thrombosis have been treated. In 140 of these treatment was started within 48 hours of the appearance of signs and symptoms. Swelling was slight or absent in 67 cases, gross in 73. Those listed with gross swelling may well have had thrombosis for longer than 48 hours, but neither complaint nor signs of abnormality had been recorded. In 60 cases symptoms had been present for 48 hours or more before start of anticoagulant therapy.
In each case treatment consisted of elevation of the foot of the bed, encouragement to move the limbs in bed and anticoagulant therapy? heparin alone in cases which had been recently operated upon, or dicoumarol or tromexan covered by an initial 2 days on intravenous and/or intramuscular heparin. A long-term follow-up has not yet been made, but the results at periods from 3 months to 2 years are shown in Table I . The course of treatment varied in length from 10 days to 3 months, being short in cases where initial limb swelling was slight and early ambulation was possible, and prolonged in cases such as an ileo-femoral thrombosis in a patient with a fractured femur where active use of the affected limb was not possible for several months. In all cases in which moderate or gross swelling had been noted the affected limb was supported by a crepe bandage or elastic stocking before the patient was allowed to walk. Pulmonary emboli occurred in 10 of these cases during treatment, one being fatal. This occurred in a man with carcinoma of the colon who had an ileo-femoral vein thrombosis in the left leg. He was treated with 7500 units of heparin 8-hourly by intravenous injection, and with physiotherapy. He died suddenly on the second day of treatment, 15 minutes after physiotherapy and 8 hours after his last dose of heparin. I feel that two mistakes were made in this case :
(0 inadequate heparinisation, and (2) an injudiciously early start of physiotherapy.
(d) Pulmonary Embolism.?Twenty-three patients in whom signs ?f pulmonary embolism were the first indications of the presence of thrombo-embolic disease received anticoagulant therapy. In only 8 of these were signs of venous thrombosis in the legs found on examination or evident later. Nineteen recovered and 4 died. In one of the 4 fatalities, a case of suprapubic cystostomy, autopsy was refused, but a clinical diagnosis of cerebral haemorrhage had been made. The second patient died of myocardial failure 11 days after the start of anticoagulant therapy, and at autopsy an old embolus was found Partially blocking the right pulmonary artery?the pathologist commented upon the absence of secondary clot. The third patient was Moribund on admission, and the fourth died within a few minutes of lodgment of a massive embolus. A single dose of heparin had been given immediately after the onset of symptoms.
In cases of pulmonary embolism it is probably only where the block is incomplete that anticoagulant therapy can be of value in preventing consecutive thrombosis. If the pulmonary trunk or both pulmonary arteries are blocked there is no time for anticoagulants to be of use.
In addition to these 23 cases, during the 4 years 1947 to 1951, 19 fatal cases of unheralded pulmonary embolism have been recorded. At autopsy, ante-mortem thrombus was found in the leg veins in 17 ; only in one of these had previous pain in the legs been noted. In the eighteenth case painless oedema of both legs had been attributed to congestive cardiac failure. In only one, the nineteenth case, was the site of origin of the clot in doubt.
(e) Recurrent Venous Thrombosis.?Sixteen patients with recurrent superficial and/or deep venous thrombosis have been treated with anticoagulants. In 10 of these patients there was also evidence of obliterate arterial disease. There was no evidence of arterial involvement lri the remaining 6 patients but they had all suffered several attacks ?f deep or superficial venous thrombosis or both, and 4 of them had also had several pulmonary emboli.
The lesions of migratory phlebitis are notoriously erratic in their appearances and disappearances, but in the first 2 cases treated with ^eparin alone for periods of 8-14 days it seemed that the lesions resolved more rapidly than on previous occasions. One of these patients did not reP?rt back but the other had a recurrence 2 weeks after the first course heparin and was given heparin again for 4 days during which period the affected segment of vein recanalised. The patient has remained free from attacks of phlebitis for 6 years. The condition proved more resistant in the remaining 8 patients who were also treated with dicoumarol or tromexan for periods of 6 weeks to 7 months. Fig. 9 illustrates the variation in dosage used in one of this group who was treated as an out-patient. The aim was to keep the prothrombin level about 50 per cent, of normal and to prevent a cumulative effect. Of the 8 patients so treated 5 have remained free of phlebitis for periods of 2 to 7 years. Two in whom arterial involvement was already gross came to amputation and one died following cardiac arrest during a subsequent operation.
The 6 patients without evidence of arterial involvement form a somewhat heterogeneous group. One of them has already been referred to earlier in this paper as the first patient to be put on anticoagulant therapy as an out-patient (p. 282). A second whose symptoms closely resemble those of the first patient has been on anticoagulant therapy for two years and each attempt to diminish or stop anticoagulants has been followed by further thrombotic incidents. It is suspected that he may have a neoplasm but to date there are no localising signs to indicate a possible site.
Although the appearance of spontaneous recurrent deep venous thrombosis may be the first sign of the presence of neoplasm, the following case illustrates another possible cause (Fig. 10) .
A man of 52 was admitted to hospital in August 1949 with spontaneous deep venous thrombosis in the right leg. This was treated by full heparinisation and had improved so much in 5 days that we were persuaded to discontinue treatment and allow him to go home. In .?Graph to illustrate the intermittent type of dosage of tromexan and the effect on prothrombin activity in a man with migratory phlebitis treated as an out-patient. Fig. 9 .?Graph to illustrate the intermittent type of dosage of tromexan and the effect on prothrombin activity in a man with migratory phlebitis treated as an out-patient.
September and October 1949 he had six minor episodes of right-sided chest pain, and in October there was a recurrence of venous thrombosis in the right leg, gross swelling and oedema of the leg being preceded by superficial phlebitis in the right thigh, pain in the right side of the chest and haemoptysis. This time he treated himself by rest in bed at home, and he improved but swelling of the right leg persisted. He came back to hospital in February 1951 with this complaint. Dental sepsis was found and tooth extraction advised, and this was done under penicillin cover, haemolytic streptococcus being isolated. Before the tooth sockets had healed, he had repeated episodes of venous thrombosis in the left forearm. When the tooth sockets had healed, he was given a 3 months' course of tromexan. When seen in March 1952 he was Well. It would appear that in this case credit for his recovery is largely due to the dental attention he received, and that anticoagulant therapy played a minor part.
Of the 3 other patients in this group one has continued to have minor attacks of superficial phlebitis in the lower limbs ; the other two remained free of symptoms for 6 months and 4 years respectively.
(/) Miscellaneous.?I do not propose to discuss details of a small group of patients who were given anticoagulant therapy because of a variety of conditions, including one case of frostbite, but will just Mention that in 5 patients who had had previous thrombo-embolic episodes and required operative treatment, a trouble-free convalescence followed prophylactic anticoagulant therapy given in the immediate Post-operative period.
Conclusions
In conclusion, what did we hope to achieve by the use of anticoagu-^ant therapy in these cases ? In cases of arterial or venous thrombosis we hoped to prevent or at v?l. least slow down consecutive thrombosis, and to permit or encourage resolution of thrombus already present. It was also hoped to prevent embolic episodes. It is too early to evaluate the results of treatment in cases of chronic obliterative arterial disease, but we have found it is possible to use tromexan for long periods in these cases treated as out-patients, and it may be that long-term prophylactic therapy will prove useful.
In cases of arterial emboli in limbs, I think anticoagulants have helped to preserve function by preventing consecutive thrombosis and blockage of collateral channels. Further embolic episodes have not been prevented.
Pulmonary emboli occurred during treatment in io of the 200 cases of venous thrombosis, being fatal in one. This incidence is considerably lower than the 30 per cent, reported by Zilliacus (1946) in untreated cases, in which the mortality was 9-3 per cent. The finding of thrombus in the leg veins of 17 of the 19 patients who died of unheralded pulmonary embolism has made us believe that it should be possible to diminish this number by making greater efforts to discover signs of thrombosis in the limbs at an earlier date.
